Tirzepatide and Psoriasis: What the TOGETHER Trials Show About Weight, Skin and Joint Inflammation

Psoriasis has long been treated as a skin disease, but dermatologists increasingly describe it as a systemic inflammatory condition that travels with obesity, insulin resistance and cardiovascular risk. That overlap raised an obvious research question once GLP-1 based medicines arrived, which was whether treating excess weight could change how well psoriasis responds to standard therapy.

Two phase 3b trials from Eli Lilly, TOGETHER-PsO and TOGETHER-PsA, tested exactly that by adding tirzepatide to the IL-17 biologic ixekizumab in adults with psoriatic disease and obesity or overweight. This article explains what those trials found, why fat tissue matters for psoriasis, and what the results do and do not mean for people living with the condition. It is educational information rather than medical advice.

Why is psoriasis linked to body weight?

Psoriasis is linked to body weight because fat tissue, particularly visceral fat, produces inflammatory signals that overlap with the immune pathways driving psoriatic plaques. Adipose tissue in people with obesity releases TNF-alpha, IL-6 and leptin while producing less of the calming hormone adiponectin, and these signals feed into the IL-23 and IL-17 axis that keeps skin cells dividing too quickly.

Population studies consistently find that psoriasis is more common and more severe in people with higher body mass index, and a widely cited pooled analysis by Armstrong and colleagues in Nutrition and Diabetes (2012) estimated roughly 66 percent higher odds of obesity among people with psoriasis. The relationship appears to run in both directions, since weight gain in adulthood is associated with a higher chance of developing psoriasis and established psoriasis is associated with later metabolic problems.

Treatment response. Higher body weight has also been associated with weaker responses to several systemic psoriasis therapies, including some biologics dosed at a fixed amount regardless of weight. This pattern is one reason researchers wanted to know whether treating obesity directly would help biologic therapy work better.

Does weight loss improve psoriasis without medication?

Weight loss through diet and exercise appears to improve psoriasis modestly in people with overweight or obesity, although the trials are small. A Danish randomized trial of a low calorie diet published in JAMA Dermatology (2013) reported meaningful improvements in quality of life scores and a trend toward lower psoriasis severity, and an Italian trial published in the British Journal of Dermatology (2014) found that a diet and exercise program improved responses in people already receiving systemic treatment.

The practical problem has always been the size and durability of lifestyle weight loss, which for most people falls in the range of 5 to 10 percent and is often partly regained. Medicines that produce larger and more sustained weight reduction made it possible to test the weight and inflammation hypothesis at a scale that diet trials could not easily reach.

What was the TOGETHER-PsO trial?

TOGETHER-PsO was a 52 week, randomized, open label phase 3b trial with blinded assessors that compared ixekizumab plus tirzepatide with ixekizumab alone in adults with moderate to severe plaque psoriasis and obesity, or overweight with at least one weight related condition. The enrolled population had an average BMI above 39, which is heavier than the populations in most earlier phase 3 psoriasis biologic trials.

The trial used composite primary endpoints that required both skin improvement and weight loss at the same time, an unusual design that reflects the idea of treating psoriasis and obesity as one connected problem rather than two separate ones.

Did tirzepatide improve skin clearance beyond weight loss?

Tirzepatide added to ixekizumab increased the share of people with completely clear skin, from 29.0 percent to 40.6 percent at week 36, which investigators described as roughly a 40 percent relative increase. The PASI 100 endpoint matters because it does not require any weight loss, so it measures the skin outcome on its own terms.

Whether the added benefit comes entirely from weight loss or partly from a direct effect of tirzepatide on inflammation cannot be separated from this trial design.

How much weight did people lose in TOGETHER-PsO?

People receiving ixekizumab plus tirzepatide lost about 18.0 percent of body weight on average by week 36, compared with about 1.1 percent among those on ixekizumab alone. That difference is close to what tirzepatide produced over a similar period in the SURMOUNT obesity trials, which suggests that psoriasis did not blunt the weight effect.

Did the benefits hold up at one year?

The combination advantage persisted through week 52 in TOGETHER-PsO, when 30.6 percent of people on ixekizumab plus tirzepatide met the PASI 100 and 10 percent weight loss endpoint, compared with 4.4 percent on ixekizumab alone. The gap widened slightly between weeks 36 and 52, which is consistent with continued weight loss in the combination arm while skin response on ixekizumab alone remained steady.

What did the TOGETHER-PsA trial find for psoriatic arthritis?

TOGETHER-PsA found that adding tirzepatide to ixekizumab improved joint outcomes in 271 adults with active psoriatic arthritis and obesity or overweight. At week 36, 31.7 percent of people on the combination reached both ACR50, a 50 percent improvement in joint disease measures, and at least 10 percent weight loss, compared with 0.8 percent on ixekizumab alone (Merola et al., Arthritis and Rheumatology 2026).

ACR50 on its own was reached by 33.5 percent of the combination group and 20.4 percent of the ixekizumab group. Investigators noted that the two arms began to separate as early as week 4, before much weight had been lost, which has prompted interest in whether tirzepatide has anti-inflammatory effects that act partly independently of weight.

How do the two TOGETHER trials compare?

The two trials shared a design, a comparator and a population defined by excess weight, but they measured different parts of psoriatic disease. The table below summarizes the main features side by side.

Is tirzepatide approved to treat psoriasis?

Tirzepatide is not approved by the FDA to treat psoriasis or psoriatic arthritis. Its approved uses are type 2 diabetes (as Mounjaro), chronic weight management, and obstructive sleep apnea in adults with obesity (as Zepbound), and any role in psoriatic disease depends on future regulatory review.

For a person with psoriasis who also meets the criteria for obesity treatment, the decision about tirzepatide rests on the weight related indication and is made by a licensed clinician. In the TOGETHER trials, tirzepatide was always given alongside a biologic, so the data say nothing about whether tirzepatide alone controls psoriasis, and nobody should stop or change a prescribed psoriasis treatment without talking to the prescribing dermatologist or rheumatologist.

What are the limitations of the TOGETHER data?

The TOGETHER trials were open label, which means participants knew whether they were receiving tirzepatide, and that knowledge can influence patient reported parts of the outcome measures even when the assessors scoring skin and joints are blinded. The trials also compared against a single biologic, so the findings may not transfer directly to other psoriasis medicines.

Longer follow up is still needed to show whether the skin and joint gains last if weight is regained, and whether improved metabolic health translates into fewer cardiovascular events in this population, which carries elevated heart risk compared with the general public.

What side effects should people expect?

The safety findings in the TOGETHER trials were reported as consistent with the known profiles of each drug, with gastrointestinal effects such as nausea, diarrhea and constipation being the most common tirzepatide related events. These effects are usually most noticeable during dose increases and tend to ease over time, and a clinician can adjust the titration schedule when they are troublesome.

The bottom line

The TOGETHER trials suggest that treating obesity with tirzepatide alongside a biologic can raise the share of people with completely clear skin or meaningful joint improvement, while producing weight loss of around 18 percent on average. People with psoriatic disease and excess weight should speak with a licensed clinician about whether weight management treatment is appropriate for them.